Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01079806 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT01079806 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 180 participants.
The verdict
NCT01079806, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection
Interventions
- DRUG Placebo
- DRUG Entecavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2010-06-30 |
| Est. Completion | 2018-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01079806
The ClinicalTrials.gov registry entry for NCT01079806 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01079806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01079806 about?
NCT01079806 is a clinical study titled "A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection". The purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection
What is the current status of trial NCT01079806?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2010-06-30. Estimated completion is 2018-03-31.
What interventions are being tested in trial NCT01079806?
The interventions under investigation include: Placebo (DRUG), Entecavir (DRUG).
Who is sponsoring clinical trial NCT01079806?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.